These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23940214)

  • 1. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.
    Moerman RV; Arends S; Meiners PM; Brouwer E; Spijkervet FK; Kroese FG; Vissink A; Bootsma H
    Ann Rheum Dis; 2014 Feb; 73(2):472-4. PubMed ID: 23940214
    [No Abstract]   [Full Text] [Related]  

  • 2. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E; Hall FC
    Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract]   [Full Text] [Related]  

  • 4. Summaries for patients. Does rituximab help patients with primary Sjögren syndrome?
    Ann Intern Med; 2014 Feb; 160(4):I-11. PubMed ID: 25006621
    [No Abstract]   [Full Text] [Related]  

  • 5. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
    Uraoka Y; Tanigawa T; Watanabe K; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Arakawa T
    Am J Gastroenterol; 2012 Aug; 107(8):1266-8. PubMed ID: 22859008
    [No Abstract]   [Full Text] [Related]  

  • 6. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
    Ciccia F; Giardina A; Rizzo A; Guggino G; Cipriani P; Carubbi F; Giacomelli R; Triolo G
    Ann Rheum Dis; 2013 May; 72(5):782-3. PubMed ID: 23264342
    [No Abstract]   [Full Text] [Related]  

  • 7. Does rituximab help patients with primary Sjögren syndrome?
    Ann Intern Med; 2014 Feb; 160(4):I-11. PubMed ID: 24727838
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
    Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
    Pollard RP; Abdulahad WH; Bootsma H; Meiners PM; Spijkervet FK; Huitema MG; Burgerhof JG; Vissink A; Kroese FG
    Ann Rheum Dis; 2013 Dec; 72(12):2048-50. PubMed ID: 23864239
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.
    Pollard RP; Abdulahad WH; Vissink A; Hamza N; Burgerhof JG; Meijer JM; Visser A; Huitema MG; Spijkervet FK; Kallenberg CG; Bootsma H; Kroese FG
    Ann Rheum Dis; 2013 Jan; 72(1):146-8. PubMed ID: 22851468
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
    Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
    Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of primary Sjögren syndrome with rituximab.
    Faustman DL; Vivino FB; Carsons SE
    Ann Intern Med; 2014 Sep; 161(5):376-7. PubMed ID: 25178574
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of primary Sjögren syndrome with rituximab. In response.
    Saraux A; Nowak E; Devauchelle-Pensec V
    Ann Intern Med; 2014 Sep; 161(5):377-8. PubMed ID: 25178575
    [No Abstract]   [Full Text] [Related]  

  • 15. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.
    Lehner GF; Brunner-Palka M; Rettenbacher T; Schmidauer R; Herold M
    Rheumatology (Oxford); 2014 Jul; 53(7):1349-50. PubMed ID: 24446469
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab in primary Sjögren's syndrome: a ten-year journey.
    Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
    Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
    Atzeni F; Sarzi-Puttini P
    Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
    Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Hatron PY; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Pers JO; Nowak E; Saraux A
    Ann Intern Med; 2014 Feb; 160(4):233-42. PubMed ID: 24727841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study.
    Abdulahad WH; Meijer JM; Kroese FG; Meiners PM; Vissink A; Spijkervet FK; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2011 Apr; 63(4):1116-23. PubMed ID: 21225693
    [No Abstract]   [Full Text] [Related]  

  • 20. Dramatic reversal of lymphocytic interstitial pneumonitis in Sjögren's syndrome with rituximab.
    Swartz MA; Vivino FB
    J Clin Rheumatol; 2011 Dec; 17(8):454. PubMed ID: 22126805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.